To effectively control the recurrence of CD19-positive B cell hematologic malignancy, the ongoing clinical trial (NCT02903810) infuses both CD19 and CD22 CAR T cells into the patients with refractory or recurrent CD19+/22+ B-lineage leukemia/lymphoma. Here, CD22 is linked to lymphoma.